Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

PEGylation improves the pharmacokinetic properties and ability of interferon gamma to inhibit growth of a human tumor xenograft in athymic mice.

Fam CM, Eisenberg SP, Carlson SJ, Chlipala EA, Cox GN, Rosendahl MS.

J Interferon Cytokine Res. 2014 Oct;34(10):759-68. doi: 10.1089/jir.2013.0067. Epub 2014 May 19.

2.

A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.

Rosendahl MS, Doherty DH, Smith DJ, Carlson SJ, Chlipala EA, Cox GN.

Bioconjug Chem. 2005 Jan-Feb;16(1):200-7.

PMID:
15656592
3.

Site-specific PEGylation enhances the pharmacokinetic properties and antitumor activity of interferon beta-1b.

Lee JI, Eisenberg SP, Rosendahl MS, Chlipala EA, Brown JD, Doherty DH, Cox GN.

J Interferon Cytokine Res. 2013 Dec;33(12):769-77. doi: 10.1089/jir.2012.0148. Epub 2013 Aug 20.

4.

Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.

Bell SJ, Fam CM, Chlipala EA, Carlson SJ, Lee JI, Rosendahl MS, Doherty DH, Cox GN.

Bioconjug Chem. 2008 Jan;19(1):299-305. Epub 2007 Nov 20.

PMID:
18020402
5.

Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor.

Doherty DH, Rosendahl MS, Smith DJ, Hughes JM, Chlipala EA, Cox GN.

Bioconjug Chem. 2005 Sep-Oct;16(5):1291-8.

6.

N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.

Baker DP, Lin EY, Lin K, Pellegrini M, Petter RC, Chen LL, Arduini RM, Brickelmaier M, Wen D, Hess DM, Chen L, Grant D, Whitty A, Gill A, Lindner DJ, Pepinsky RB.

Bioconjug Chem. 2006 Jan-Feb;17(1):179-88.

PMID:
16417267
7.

Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.

Basu A, Yang K, Wang M, Liu S, Chintala R, Palm T, Zhao H, Peng P, Wu D, Zhang Z, Hua J, Hsieh MC, Zhou J, Petti G, Li X, Janjua A, Mendez M, Liu J, Longley C, Zhang Z, Mehlig M, Borowski V, Viswanathan M, Filpula D.

Bioconjug Chem. 2006 May-Jun;17(3):618-30.

PMID:
16704199
8.

Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity.

Long DL, Doherty DH, Eisenberg SP, Smith DJ, Rosendahl MS, Christensen KR, Edwards DP, Chlipala EA, Cox GN.

Exp Hematol. 2006 Jun;34(6):697-704.

9.

PEGylation improves pharmacokinetic profile, liver uptake and efficacy of Interferon gamma in liver fibrosis.

Bansal R, Post E, Proost JH, de Jager-Krikken A, Poelstra K, Prakash J.

J Control Release. 2011 Sep 25;154(3):233-40. doi: 10.1016/j.jconrel.2011.05.027. Epub 2011 Jun 12.

PMID:
21664391
10.

Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration.

Mcleod VM, Chan LJ, Ryan GM, Porter CJ, Kaminskas LM.

J Pharm Sci. 2015 Apr;104(4):1421-30. doi: 10.1002/jps.24353. Epub 2015 Jan 28.

PMID:
25631360
11.

A long-acting, mono-PEGylated human growth hormone analog is a potent stimulator of weight gain and bone growth in hypophysectomized rats.

Cox GN, Rosendahl MS, Chlipala EA, Smith DJ, Carlson SJ, Doherty DH.

Endocrinology. 2007 Apr;148(4):1590-7. Epub 2007 Jan 18.

12.

Suppression of hepatocellular carcinoma proliferation and hepatitis B surface antigen secretion with interferon-λ1 or PEG-interferon-λ1.

Tian S, Hui X, Fan Z, Li Q, Zhang J, Yang X, Ma X, Huang B, Chen D, Chen H.

FASEB J. 2014 Aug;28(8):3528-39. doi: 10.1096/fj.14-250704. Epub 2014 Apr 25.

13.

Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.

Jo YW, Youn YS, Lee SH, Kim BM, Kang SH, Yoo M, Choi EC, Lee KC.

Int J Pharm. 2006 Feb 17;309(1-2):87-93. Epub 2006 Jan 9.

PMID:
16406701
14.

Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.

Pepinsky RB, LePage DJ, Gill A, Chakraborty A, Vaidyanathan S, Green M, Baker DP, Whalley E, Hochman PS, Martin P.

J Pharmacol Exp Ther. 2001 Jun;297(3):1059-66.

15.

Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).

Pan LQ, Wang HB, Lai J, Xu YC, Zhang C, Chen SQ.

Biomaterials. 2013 Dec;34(36):9115-23. doi: 10.1016/j.biomaterials.2013.08.020. Epub 2013 Aug 24.

PMID:
23981355
16.

Long-acting forms of Sonic hedgehog with improved pharmacokinetic and pharmacodynamic properties are efficacious in a nerve injury model.

Pepinsky RB, Shapiro RI, Wang S, Chakraborty A, Gill A, Lepage DJ, Wen D, Rayhorn P, Horan GS, Taylor FR, Garber EA, Galdes A, Engber TM.

J Pharm Sci. 2002 Feb;91(2):371-87.

PMID:
11835197
17.

Development of copper-catalyzed azide-alkyne cycloaddition for increased in vivo efficacy of interferon β-1b by site-specific PEGylation.

Nairn NW, Shanebeck KD, Wang A, Graddis TJ, VanBrunt MP, Thornton KC, Grabstein K.

Bioconjug Chem. 2012 Oct 17;23(10):2087-97. doi: 10.1021/bc300295x. Epub 2012 Sep 28.

PMID:
22988919
18.

Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo.

Sayers TJ, Wiltrout TA, McCormick K, Husted C, Wiltrout RH.

Cancer Res. 1990 Sep 1;50(17):5414-20.

19.

In vivo pharmacokinetics, immunogenicity and mechanism of PEGylated antitumor polypeptide.

Liu Z, Li W, Xu HM, Huang X, Pan L, Ren Y, Yang Y, Li Y, Pu C, Zhang C.

Curr Pharm Des. 2012;18(12):1655-62.

PMID:
22283767
20.

Site-specific PEGylation of bone morphogenetic protein-2 cysteine analogues.

Hu J, Duppatla V, Harth S, Schmitz W, Sebald W.

Bioconjug Chem. 2010 Oct 20;21(10):1762-72. doi: 10.1021/bc9005706.

PMID:
20886828
Items per page

Supplemental Content

Write to the Help Desk